About Anthony Aiudi
Anthony Aiudi is a director at AdvanCell.
Form D filings also name Anthony Aiudi as an executive officer, director and promoter at Neutrolis and a director at i2O Therapeutics.
Anthony Aiudi first appears on SEC filings in 2021.
Experience
This experience comes from Anthony Aiudi's profile and from SEC filings. For roles taken from filings, the years are when the filings name Anthony Aiudi in the role, so the role may have started earlier or lasted longer.
AdvanCell, Inc. Current
Director
2022 – Present · Cambridge, MA
Develops targeted radiation treatments for people with cancer.
Neutrolis Inc. Current
Chief Executive Officer (2021 – Present)
Director
2021 – Present · Cambridge, MA
FI
Fount Bio, Inc. Current
Chairman and Board Member
2021 – Present
VA
Valitor Current
Chairman and Board Member
2021 – Present
BI
Biothea Pharma Inc. Current
Board Member
2021 – Present
ML
Morningside Technology Advisory LLC Current
Investor
2020 – Present
BP
Blueberry Pediatrics
Board Member
2023 – 2025
IN
Innodem Neurosciences
Board Member
2023 – 2025
CY
Cyted
Board Member
2021 – 2025
EI
Evantigen, Inc.
President
2022 – 2024
ME
Merck
Senior Clinical Development Scientist
2015
CP
Cubist Pharmaceuticals
Post-Doctoral Clinical Research Fellow
2014 – 2015
CP
CharterCARE Health Partners
Pharmacist In Training
2011 – 2014
CC
CVS Caremark Corporation
Pharmacist In Training
2009 – 2012
Key Colleagues at Startups
The people Anthony Aiudi works with at each company, as listed on that company's latest Form D.
AdvanCell, Inc. · Form D, Jul 16, 2026
AK
Andrew Kay
Director
PL
Philina Lee
Chief Executive Officer and director
JB
Jamil Beg
Director
KC
Kevin Cameron
Director
CG
Christopher Gagliardi
Director
BM
Bali Muralidhar
Director
WL
Wing Cheong Lam
Director
AA
Andrew Adamovich
Founder & Managing Director, Australia
AP
Aaron Pickett
Secretary
NE
Nik Economopoulos
Director
Neutrolis Inc. · Form D, Jul 15, 2025
JS
John Sundy
Director
GC
Gerald Chan
Director
TF
Toby Fox
Executive officer, director and promoter
AR
Abdul Rahamathullah
Executive officer, director and promoter
i2O Therapeutics, Inc. · Form D, Oct 18, 2023
CG
Christopher Gagliardi
Director
KG
Kurt Graves
Chief Executive Officer and director